Cargando…

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma

OBJECTIVE: To investigate the effects of mTOR inhibition on drug resistance in lung adenocarcinoma after combined radiation and erlotinib therapy. RESULTS: Combined radiation and erlotinib therapy produced clear radiosensitization effects both in vitro and in vivo; however, tumor cells remained drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhuang, Hongqing, Bai, Jing, Chang, Joe Y., Yuan, Zhiyong, Wang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356691/ https://www.ncbi.nlm.nih.gov/pubmed/27713162 http://dx.doi.org/10.18632/oncotarget.12423

Ejemplares similares

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2013)

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy
por: Zhuang, Hongqing, et al.
Publicado: (2014)

Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor
por: Zhuang, Hongqing, et al.
Publicado: (2019)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues
por: Zhuang, Hongqing, et al.
Publicado: (2019)

Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
por: Xie, Caifeng, et al.
Publicado: (2015)

Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma
por: Kurishima, Koichi, et al.
Publicado: (2014)

Analysis of risk and predictors of brain radiation necrosis after radiosurgery
por: Zhuang, Hongqing, et al.
Publicado: (2015)

Erlotinib: An enhancer of radiation therapy in nasopharyngeal carcinoma
por: ZHANG, HUAN-HUAN, et al.
Publicado: (2013)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
por: Wang, Hui-Li, et al.
Publicado: (2019)

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022)

Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis
por: Wang, Zhongqiu, et al.
Publicado: (2016)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer
por: Zhuang, Hongqing, et al.
Publicado: (2014)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study
por: Zhuang, Hongqing, et al.
Publicado: (2020)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
por: HUANG, CHU-YUN, et al.
Publicado: (2014)

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma
por: Bell, Ann T., et al.
Publicado: (2017)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis
por: Zhuang, Hongqing, et al.
Publicado: (2016)

M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way
por: Li, Kai, et al.
Publicado: (2021)

Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone
por: Guan, Yin, et al.
Publicado: (2014)

Down-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression
por: Liao, Jinrong, et al.
Publicado: (2017)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure?
por: Kus, Tulay, et al.
Publicado: (2015)

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation
por: Niwa, Hideyuki, et al.
Publicado: (2018)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kq1aknmtjlfbiq9rv1q99fumnp